Abstract：
UNASSIGNED: Acute interstitial nephritis (AIN) is a complication of drugs that may cause permanent kidney injury. AIN has been reported in patients with inflammatory bowel disease (IBD) treated with the integrin inhibitor vedolizumab. Through systematic review of existing literature, we aimed to identify and describe cases of AIN in patients with IBD treated with vedolizumab.
UNASSIGNED: We searched Medline, Embase, Cochrane, and Web of Science Core Collection between 1 January 2009 and 25 April 2023. The search yielded 1473 publications. Titles and abstracts were screened by two independent reviewers. Seventy publications were reviewed in full-text. Eight met the inclusion criteria. Clinical characteristics of AIN cases were extracted. Case causality assessment was performed according to two international adverse drug reaction probability assessment scales. Results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
UNASSIGNED: Nine biopsy-confirmed cases of AIN were reported in six patients with ulcerative colitis and three with Crohn\'s disease. Mean age at AIN onset was 36 years (range = 19-58) and the majority of patients were females (n = 6/9). Time from vedolizumab treatment initiation to AIN onset spanned from hours to 12 months. Common symptoms were fever and malaise. Creatinine levels were elevated in all patients. Five patients sustained permanent kidney injury.
UNASSIGNED: Our findings suggest that vedolizumab, although rarely, could cause AIN in patients with IBD. Awareness of laboratory findings and symptoms consistent with AIN, along with monitoring of the kidney function, could be warranted in patients with IBD treated with vedolizumab.
UNASSIGNED: We searched Medline, Embase, Cochrane, and Web of Science Core Collection between 1 January 2009 and 25 April 2023. The search yielded 1473 publications. Titles and abstracts were screened by two independent reviewers. Seventy publications were reviewed in full-text. Eight met the inclusion criteria. Clinical characteristics of AIN cases were extracted. Case causality assessment was performed according to two international adverse drug reaction probability assessment scales. Results were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
UNASSIGNED: Nine biopsy-confirmed cases of AIN were reported in six patients with ulcerative colitis and three with Crohn\'s disease. Mean age at AIN onset was 36 years (range = 19-58) and the majority of patients were females (n = 6/9). Time from vedolizumab treatment initiation to AIN onset spanned from hours to 12 months. Common symptoms were fever and malaise. Creatinine levels were elevated in all patients. Five patients sustained permanent kidney injury.
UNASSIGNED: Our findings suggest that vedolizumab, although rarely, could cause AIN in patients with IBD. Awareness of laboratory findings and symptoms consistent with AIN, along with monitoring of the kidney function, could be warranted in patients with IBD treated with vedolizumab.
摘要：
■急性间质性肾炎（AIN）是一种可能导致永久性肾损伤的药物并发症。已经报道了用整联蛋白抑制剂维多珠单抗治疗的炎症性肠病(IBD)患者中的AIN。通过对现有文献的系统回顾，我们旨在确定和描述接受维多珠单抗治疗的IBD患者中AIN的病例.
■我们搜索了Medline，Embase,科克伦,以及2009年1月1日至2023年4月25日之间的WebofScience核心合集。搜索产生了1473种出版物。标题和摘要由两名独立的审稿人筛选。全文审查了70份出版物。八个符合纳入标准。提取AIN病例的临床特征。根据两种国际药物不良反应概率评估量表进行病例因果关系评估。根据系统评价和荟萃分析（PRISMA）指南的首选报告项目报告结果。
■在6例溃疡性结肠炎和3例克罗恩病患者中报告了9例经活检证实的AIN病例。AIN发病的平均年龄为36岁（范围=19-58），大多数患者为女性（n=6/9）。从维多珠单抗治疗开始到AIN发作的时间从数小时到12个月。常见的症状是发烧和不适。所有患者的肌酐水平均升高。5例患者持续永久性肾损伤。
■我们的研究结果表明，维多珠单抗，虽然很少,可能导致IBD患者出现AIN。意识到与AIN一致的实验室发现和症状，同时监测肾功能，维多珠单抗治疗的IBD患者可能是合理的。
■我们搜索了Medline，Embase,科克伦,以及2009年1月1日至2023年4月25日之间的WebofScience核心合集。搜索产生了1473种出版物。标题和摘要由两名独立的审稿人筛选。全文审查了70份出版物。八个符合纳入标准。提取AIN病例的临床特征。根据两种国际药物不良反应概率评估量表进行病例因果关系评估。根据系统评价和荟萃分析（PRISMA）指南的首选报告项目报告结果。
■在6例溃疡性结肠炎和3例克罗恩病患者中报告了9例经活检证实的AIN病例。AIN发病的平均年龄为36岁（范围=19-58），大多数患者为女性（n=6/9）。从维多珠单抗治疗开始到AIN发作的时间从数小时到12个月。常见的症状是发烧和不适。所有患者的肌酐水平均升高。5例患者持续永久性肾损伤。
■我们的研究结果表明，维多珠单抗，虽然很少,可能导致IBD患者出现AIN。意识到与AIN一致的实验室发现和症状，同时监测肾功能，维多珠单抗治疗的IBD患者可能是合理的。
